Alzheimer's treatment

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for aducanumab, an experimental treatment for early Alzheimer's disease, Biogen and its Japanese partner Eisai announced on Tuesday.

Phase 3 clinical studies of aducanumab were discontinued in March. The trials were halted because results of a futility analysis found they were unlikely to meet their primary goals at completion.
On Tuesday, Biogen announced that a new analysis, which included more patients, showed a significant reduction in clinical decline in one trial. Results for some patients in another study support those findings, as well.


The data showed that patients who received aducanumab experienced significant benefits on measures of cognition and function, including memory, orientation and language, according to Biogen... https://edition.cnn.com/2019/10/22/health/biogen-alzheimers-drug-fda/index.html

Popular posts from this blog

The Unreality of Wasseypur: Javed Iqbal

History Archive: Communist Party of India's resolution on Pakistan and National Unity, September 1942

Pakistan's First Law & Labour Minister, Jogendra Nath Mandal's Resignation Letter, October 1950

The Almond Trees by Albert Camus (1940)

Book review: Thirteen Months in China: A Subaltern Indian and the Colonial World

Ben Marks - The Mao Mango Cult of 1968 and the Rise of China's Working Class

Karl Marx: Letter to Abraham Lincoln, President of the United States of America; 1865